Cancer Causes & Control

, Volume 18, Issue 4, pp 375–384 | Cite as

Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia

  • Jay H. Fowke
  • Saundra S. Motley
  • Marcia Wills
  • Michael S. Cookson
  • Raoul S. Concepcion
  • Charles W. Eckstein
  • Sam S. Chang
  • Joseph A. SmithJr
Original Paper

Abstract

The relationship between obesity and prostate cancer remains unclear. We investigated the effect of prostate volume on the obesity and prostate cancer association. With a multi-centered, rapid-recruitment protocol, weight and body size measurements were collected prior to diagnosis, and medical charts were reviewed for pathology results (n = 420 controls, 119 high-grade prostatic intraepithelial neoplasia (PIN) cases, and 286 cancer cases (41% Gleason > 6). In multivariable logistic regression models adjusting for age, PSA levels and history, DRE results, and number of cores at biopsy, the association between BMI and cancer was restricted to men with a smaller prostate volume (volume < 40 cm3: ORBMI ≥ 30 = 2.17 (1.09, 4.32), ptrend = 0.02; volume ≥ 40 cm3: ORBMI ≥ 30 = 0.77 (0.34, 1.77), ptrend = 0.17; pinteraction = 0.03). Similarly, the WHR and PIN association was significantly modified by prostate volume (volume < 40 cm3: OR(WHR: Tertile 3 vs. T1) = 3.76 (1.54, 9.21) (ptrend < 0.01); volume ≥ 40 m3: OR(WHR: T3 vs. T1) = 0.63 (0.32, 1.23) (ptrend = 0.17); pinteraction < 0.01). In conclusion, prostate volume acts as a modifier, and BMI and WHR are significantly associated with prostate cancer or PIN, respectively, in the absence of biopsy sampling error derived from obesity-related prostate enlargement.

Keywords

Obesity Prostate cancer High-grade prostatic intraepithelial neoplasia Prostate volume Detection bias 

Abbreviations

BMI

Body mass index

WST

Waist circumference

WHR

Waist-to-hip ratio

PIN

High-grade prostatic intraepithelial neoplasia

OR

Odds ratio

CI

Confidence interval

References

  1. 1.
    Nilsen TIL, Vatten LJ (1999) Anthropometry and prostate cancer risk: a prospective study of 22,248 Norwegian men. Cancer Causes Control 10:269–275PubMedCrossRefGoogle Scholar
  2. 2.
    Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA (2000) Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol 151:541–549PubMedGoogle Scholar
  3. 3.
    Hubbard JS, Rohrmann S, Landis PK, et al (2004) Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology 63:253–258PubMedCrossRefGoogle Scholar
  4. 4.
    Mills PK, Beeson L, Phillips RL, Fraser GE (1989) Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 64:598–604PubMedCrossRefGoogle Scholar
  5. 5.
    LeMarchand L, Kolonel LN, Wilkins LR, Myers BC, Hirohata T (1994) Animal fat consumption and prostate cancer: a prospective study in Hawaii. Epidemiology 5:276–282CrossRefGoogle Scholar
  6. 6.
    Whittemore AS, Paffenbarger RS, Anderson K, Lee JE (1985) Early precursors of site-specific cancers in college men and women. JNCI 74:43–51PubMedGoogle Scholar
  7. 7.
    Severson RK, Grove JS, Nomura A, Stemmermann GN (1988) Body mass and prostatic cancer: a prospective study. Br Med J 297:713–715CrossRefGoogle Scholar
  8. 8.
    Giovannucci E, Rimm EB, Liu Y et al (2003) Body mass index and risk of prostate cancer in U.S. health professionals. JNCI Cancer Spectrum 95:1240–4Google Scholar
  9. 9.
    Andersson S-O, Wolk A, Bergstrom R et al (1997) Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. JNCI 89:385–389PubMedCrossRefGoogle Scholar
  10. 10.
    Gronberg H, Damber L, Damber J-E (1996) Total food consumption and body mass index in relation to prostate cancer risk: a case-control study in Sweden with prospectively collected exposure data. J Urol 155:969–974PubMedCrossRefGoogle Scholar
  11. 11.
    Engeland A, Tretli S, Bjorge T (2005) Height, body mass index, and prostate cancer: a follow-up of 950,000 Norwegian men. Br J Cancer 69:1237–1242Google Scholar
  12. 12.
    Thune I, Lund E (1994) Physical activity and the risk of prostate and testicular cancer: a cohort study of 53,000 Norweigian men. Cancer Causes Control 5:549–556PubMedCrossRefGoogle Scholar
  13. 13.
    Aziz NM, Hartman T, Barrett M (2000) Weight and prostate cancer in the Alpha-Tocopherol Beta-Carotene Cancer Prevention (ATBC) Trial. Am Soc Clin Oncol Abst. # 647Google Scholar
  14. 14.
    Rodriguez C, Freedland SJ, Deka A et al (2006) Body mass index, weight change, and risk of prostate cancer in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev 16(1):63–69PubMedCrossRefGoogle Scholar
  15. 15.
    Bradbury BD, Wilk JB, Kaye JA (2005) Obesity and the risk of prostate cancer (United States). Cancer Causes Control 16:637–641PubMedCrossRefGoogle Scholar
  16. 16.
    Porter MP, Stanford JL (2005) Obesity and the risk of prostate cancer. The Prostate 62:316–321PubMedCrossRefGoogle Scholar
  17. 17.
    von Hafe P, Pina F, Perez A, Tavares M, Barros H (2004) Visceral fat accumulation as a risk factor for prostate cancer. Obes Res 12:1930–1935Google Scholar
  18. 18.
    Hsing AW, Deng J, Sesterhenn IA et al (2000) Body size and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 9:1335–1341PubMedGoogle Scholar
  19. 19.
    Gong Z, Neuhouser ML, Goodman PJ et al (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 15:1977–1983PubMedCrossRefGoogle Scholar
  20. 20.
    Tande AJ, Platz EA, Folsom AR (2006) The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 164:1094–1102PubMedCrossRefGoogle Scholar
  21. 21.
    Sakr WA, Grignon DJ, Crissman JD et al (1994) High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. In Vivo 8:439–444PubMedGoogle Scholar
  22. 22.
    Fontaine KR, Heo M, Allison DB (2005) Obesity and prostate cancer screening in the USA. Public Health 119:694–698PubMedCrossRefGoogle Scholar
  23. 23.
    Fowke JH, Signorello LB, Underwood W, Ukoli FA, Blot WJ (2006) Obesity and prostate cancer screening among African-American and Caucasian men. Prostate 66:1371–1380PubMedCrossRefGoogle Scholar
  24. 24.
    Baillargeon J, Pollock BH, Kristal AR et al (2005) The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103:1092–1095PubMedCrossRefGoogle Scholar
  25. 25.
    Kristal AR, Chi C, Tangen C, Goodman PJ, Etzioni R, Thompson IM (2005) Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 106:320–328CrossRefGoogle Scholar
  26. 26.
    Fowke JH, Signorello LB, Chang SS et al (2006) Effects of obesity and height on PSA and percent free PSA levels among African-American and Caucasian Men. Cancer 107:2361–2367PubMedCrossRefGoogle Scholar
  27. 27.
    Soygur T, Kupeli B, Aydos K, Kupeli S, Arikan N, Muftuoglu YZ (1996) Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels. Int Urol Nephrol 28:55–59PubMedCrossRefGoogle Scholar
  28. 28.
    Sarma AV, Jaffe CA, Schottenfeld D et al (2002) Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. Urology 59:362–367PubMedCrossRefGoogle Scholar
  29. 29.
    Parsons JK, Carter HB, Partin AW et al (2006) Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 91:2562–2568PubMedCrossRefGoogle Scholar
  30. 30.
    Freedland SJ, Platz EA, Presti JC Jr et al (2006) Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 175:500–504PubMedCrossRefGoogle Scholar
  31. 31.
    Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D (1998) Components of the metabolic syndrome—risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1:157–162PubMedCrossRefGoogle Scholar
  32. 32.
    Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW (2002) Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 168:599–604PubMedCrossRefGoogle Scholar
  33. 33.
    Presti JC, Lee U, Brooks JD, Terris MK (2004) Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population. J Urol 171:2199–2202PubMedCrossRefGoogle Scholar
  34. 34.
    Kulkarni GS, Al-Azab R, Lockwood G et al (2006) Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 175:505–509PubMedCrossRefGoogle Scholar
  35. 35.
    Freedland SJ, Terris MK, Platz EA, Presti J (2005) Body mass index as a predictor of prostate cancer: Development versus detection on biopsy. Urology 66:108–113PubMedCrossRefGoogle Scholar
  36. 36.
    Thompson IM, Goodman PJ, Tangen CM et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:213–222CrossRefGoogle Scholar
  37. 37.
    Epstein JI, Herawi M (2006) Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 175:820–834PubMedCrossRefGoogle Scholar
  38. 38.
    Bostwick DG, Foster CS (1999) Predictive factors in prostate cancer: current concepts from the 1999 college of American Pathologists Conference on solid tumor prognostic factors and the 1999 World Health Organization Second Internaitonal Consultation of prostate cancer. Semin Oncol 17:222–272Google Scholar
  39. 39.
    Bostwick DG (1999) Prostatic intraepithelial neoplasia is a risk factor for cancer. Semin Oncol 17:187–198Google Scholar
  40. 40.
    Davidson D, Bostwick DG, Qian J et al (1995) Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol 154:1295–1299PubMedCrossRefGoogle Scholar
  41. 41.
    Häggman MJ, Macoska JA, Wojno KJ, Oesterling JE (1997) The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J Urol 158:12–22PubMedCrossRefGoogle Scholar
  42. 42.
    Nelson WG, DeMarzo AM, Isaacs WB (2003) Prostate cancer. N Engl J Med 349:366–381PubMedCrossRefGoogle Scholar
  43. 43.
    Tuma RS (2006) Split prostate cancer four ways, Willett Says. JNCI Cancer Spectrum 98:959–960CrossRefGoogle Scholar
  44. 44.
    Rohrmann S, Smit E, Giovannucci E, Platz EA (2005) Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes Relat Metab Disord 29:310–316CrossRefGoogle Scholar
  45. 45.
    Giovannucci E, Rimm EB, Chute C et al (1994) Obesity and benign prostatic hyperplasia. Am J Epidemiol 140:989–1002PubMedGoogle Scholar
  46. 46.
    Cottam DR, Mattar SG, Barinas-Mitchell E et al (2004) The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg 14:589–600PubMedCrossRefGoogle Scholar
  47. 47.
    Wannamethee SG, Shaper AG, Morris RW, Whincup PH (2005) Measures of adiposity in the identification of metabolic abnormalities in elderly men. Am J Clin Nutr 81:1313–1321PubMedGoogle Scholar
  48. 48.
    National Institutes of Health (2006) Determination of degree of abdominal obesity. http://www.nhlbi.nih.gov/guidelines/obesity/e_txtbk/txgd/4112.htm
  49. 49.
    Clement K, Viguerie N, Poitou C et al (2004) Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 18:1657–1659PubMedCrossRefGoogle Scholar
  50. 50.
    Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350:2239–2246PubMedCrossRefGoogle Scholar
  51. 51.
    Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F, Stampfer MJ (1995) A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 26:40–49PubMedCrossRefGoogle Scholar
  52. 52.
    Platz EA, Leitzmann MF, Rifai N et al (2005) Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 14:1262–1269PubMedCrossRefGoogle Scholar
  53. 53.
    Platz EA, De Marzo AM, Giovannucci E (2004) Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era. J Cell Biochem 91:553–571PubMedCrossRefGoogle Scholar
  54. 54.
    Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM (2004) Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA 291:2847–2850PubMedCrossRefGoogle Scholar
  55. 55.
    Ford ES, Mokdad AH, Giles WH (2003) Trends in waist circumference among U.S. adults. Obes Res 11:1223–1231PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Jay H. Fowke
    • 1
  • Saundra S. Motley
    • 1
  • Marcia Wills
    • 3
  • Michael S. Cookson
    • 2
  • Raoul S. Concepcion
    • 2
    • 4
  • Charles W. Eckstein
    • 2
    • 4
  • Sam S. Chang
    • 2
  • Joseph A. SmithJr
    • 2
  1. 1.Vanderbilt Epidemiology CenterVanderbilt University Medical CenterNashvilleUSA
  2. 2.Department of Urologic SurgeryVanderbilt University Medical CenterNashvilleUSA
  3. 3.Department of PathologyVanderbilt University Medical CenterNashvilleUSA
  4. 4.Urology Associates P.C.NashvilleUSA

Personalised recommendations